In the fast-evolving landscape of precision oncology, a new player has entered the stage with ambitions as bold as its origins. Seattle-based Lila Biologics announced its official launch this week alongside a high-profile global licensing and multi-target collaboration with Eli Lilly and Company to discover and develop targeted radioligand therapies (TRTs) for solid tumors.

The news marks not only the arrival of another spinout from the Institute for Protein Design (IPD) at the University of Washington—home to the celebrated protein engineer and Nobel laureate David Baker, PhD—but also a pivotal moment for a nascent company that has spent just two years building its scientific platform.

The partnership marks not only Lila’s public debut but also what co-founders Anindya Roy, PhD and Jake

See Full Page